2 Global Cancer Diagnostics Quarterly Market Size Analysis

• 2.1 Cancer Diagnostics Business Impact Assessment - COVID-19
  • 2.1.1 Global Cancer Diagnostics Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Cancer Diagnostics Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 By Players, Global Cancer Diagnostics Quarterly Market Size, 2019 VS 2020
• 3.2 By Players, Cancer Diagnostics Headquarters and Area Served
• 3.3 Date of Key Players Enter into Cancer Diagnostics Market
• 3.4 Key Players Cancer Diagnostics Product Offered
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Cancer Diagnostics Segments, By Type

• 4.1 Introduction
  • 1.4.1 Platform-based
  • 1.4.2 Instrument-based
• 4.2 By Type, Global Cancer Diagnostics Market Size, 2019-2021

5 Impact of Covid-19 on Cancer Diagnostics Segments, By Application

• 5.1 Overview
  • 5.5.1 Breast Cancer
  • 5.5.2 Lung Cancer
  • 5.5.3 Colorectal Cancer
  • 5.5.4 Melanoma
  • 5.5.5 Others
• 5.2 By Application, Global Cancer Diagnostics Market Size, 2019-2021
  • 5.2.1 By Application, Global Cancer Diagnostics Market Size by Application, 2019-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Becton, Dickinson and Company
  • 7.1.1 Becton, Dickinson and Company Business Overview
  • 7.1.2 Becton, Dickinson and Company Cancer Diagnostics Quarterly Revenue, 2020
  • 7.1.3 Becton, Dickinson and Company Cancer Diagnostics Product Introduction
  • 7.1.4 Becton, Dickinson and Company Response to COVID-19 and Related Developments
• 7.2 GE Healthcare
  • 7.2.1 GE Healthcare Business Overview
  • 7.2.2 GE Healthcare Cancer Diagnostics Quarterly Revenue, 2020
  • 7.2.3 GE Healthcare Cancer Diagnostics Product Introduction
  • 7.2.4 GE Healthcare Response to COVID-19 and Related Developments
• 7.3 Abbott
  • 7.3.1 Abbott Business Overview
  • 7.3.2 Abbott Cancer Diagnostics Quarterly Revenue, 2020
  • 7.3.3 Abbott Cancer Diagnostics Product Introduction
  • 7.3.4 Abbott Response to COVID-19 and Related Developments
• 7.4 Roche
  • 7.4.1 Roche Business Overview
  • 7.4.2 Roche Cancer Diagnostics Quarterly Revenue, 2020
  • 7.4.3 Roche Cancer Diagnostics Product Introduction
  • 7.4.4 Roche Response to COVID-19 and Related Developments
• 7.5 Thermo Fisher Scientific
  • 7.5.1 Thermo Fisher Scientific Business Overview
  • 7.5.2 Thermo Fisher Scientific Cancer Diagnostics Quarterly Revenue, 2020
  • 7.5.3 Thermo Fisher Scientific Cancer Diagnostics Product Introduction
  • 7.5.4 Thermo Fisher Scientific Response to COVID-19 and Related Developments
• 7.6 Agilent Technologies
  • 7.6.1 Agilent Technologies Business Overview
  • 7.6.2 Agilent Technologies Cancer Diagnostics Quarterly Revenue, 2020
  • 7.6.3 Agilent Technologies Cancer Diagnostics Product Introduction
  • 7.6.4 Agilent Technologies Response to COVID-19 and Related Developments
• 7.7 Illumina
  • 7.7.1 Illumina Business Overview
  • 7.7.2 Illumina Cancer Diagnostics Quarterly Revenue, 2020
  • 7.7.3 Illumina Cancer Diagnostics Product Introduction
  • 7.7.4 Illumina Response to COVID-19 and Related Developments
• 7.8 Siemens Healthcare
  • 7.8.1 Siemens Healthcare Business Overview
  • 7.8.2 Siemens Healthcare Cancer Diagnostics Quarterly Revenue, 2020
  • 7.8.3 Siemens Healthcare Cancer Diagnostics Product Introduction
  • 7.8.4 Siemens Healthcare Response to COVID-19 and Related Developments
• 7.9 C.R. Bard
  • 7.9.1 C.R. Bard Business Overview
  • 7.9.2 C.R. Bard Cancer Diagnostics Quarterly Revenue, 2020
  • 7.9.3 C.R. Bard Cancer Diagnostics Product Introduction
  • 7.9.4 C.R. Bard Response to COVID-19 and Related Developments

8 Key Findings

9 Appendix

• 9.1 About US

This report covers market size and forecasts of Cancer Diagnostics, including the following market information:
Global Cancer Diagnostics Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Cancer Diagnostics Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Cancer Diagnostics Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Cancer Diagnostics Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)

Key market players
Major competitors identified in this market include Becton, Dickinson and Company, GE Healthcare, Abbott, Roche, Thermo Fisher Scientific, Agilent Technologies, Illumina, Siemens Healthcare, C.R. Bard, etc.

Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)

Based on the Type:
Platform-based
Instrument-based

Based on the Application:
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Others